Equities
Health CareMedical Equipment and Services
  • Price (USD)27.18
  • Today's Change0.48 / 1.80%
  • Shares traded430.25k
  • 1 Year change-17.89%
  • Beta0.6087
Data delayed at least 15 minutes, as of Dec 03 2022.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. It is focused on the repair, regeneration and replacement of soft and hard tissue. The Company operates through three segments: Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that helps surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

  • Revenue in USD (TTM)5.21bn
  • Net income in USD496.00m
  • Incorporated1937
  • Employees18.00k
  • Location
    Smith & Nephew PLCBuilding 5, Croxley Park, Hatters LaneWATFORD WD18 8YEUnited KingdomGBR
  • Phone+44 207 401 7646
  • Fax+44 207 930 3353
  • Websitehttps://www.smith-nephew.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SN.:LSE since
announced
Transaction
value
Engage SurgicalDeal completed19 Jan 202219 Jan 2022Deal completed-12.28%135.00m
Data delayed at least 20 minutes, as of Dec 02 2022 16:45 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
DENTSPLY SIRONA Inc4.01bn-843.00m6.81bn15.00k--1.88--1.70-3.94-3.9418.4916.810.47673.235.75267,133.30-10.03-4.12-11.72-4.6454.6353.59-21.04-9.971.046.000.3543--26.712.47663.01-0.89522.406.76
Inspire Medical Systems Inc348.35m-50.42m6.92bn485.00--14.68--19.86-1.82-1.8212.5916.310.8643.599.27718,255.70-12.51-20.41-13.94-22.5684.1884.19-14.47-33.699.75-94.560.00--102.2870.0226.50--72.46--
Globus Medical Inc998.37m155.21m7.48bn2.40k49.394.2433.507.501.521.529.7217.670.51370.98665.46415,985.807.999.698.5810.4874.4775.6115.5517.564.39--0.000.0021.4311.1845.867.416.82--
Masimo Corp1.75bn170.85m7.65bn2.20k48.146.1127.044.383.023.0231.1223.830.72422.256.18793,826.807.0816.308.5319.0054.9965.969.7821.401.28--0.43520.008.3411.69-4.43-5.897.48--
Penumbra Inc829.93m-30.51m8.01bn3.80k--8.22--9.65-0.8131-0.813121.8625.650.72331.065.37218,402.10-2.661.85-2.982.1162.9264.36-3.682.292.92-156.790.02720.0033.4023.21133.65-18.639.21--
Shockwave Medical Inc429.89m88.03m9.03bn657.00106.2225.3797.9221.012.352.3511.579.851.111.129.13654,322.7022.72--25.88--86.01--20.48--6.0231.340.0401--249.83--86.09------
Henry Schein, Inc.12.61bn638.23m11.29bn21.60k18.133.1212.960.89564.594.5990.7426.701.494.888.24583,635.307.706.2712.9911.2130.2329.995.184.800.996736.380.17850.0022.551.3956.714.492.40--
Teleflex Incorporated2.79bn412.27m11.38bn14.00k27.872.9217.734.078.718.7159.0283.040.40512.507.07199,639.905.985.576.536.1054.7055.2214.7513.901.5211.290.304817.9710.748.5144.4715.396.150.00
Smith & Nephew plc (ADR)5.21bn496.00m11.66bn18.00k24.042.2010.812.241.131.1311.8912.370.49560.80754.13283,793.304.726.695.908.0871.0372.549.5112.340.83567.990.349152.9014.302.2216.96-7.740.8033--
Align Technology, Inc.3.86bn510.76m15.50bn22.54k30.724.1924.514.016.466.4648.9747.300.66844.184.51171,438.308.8325.1212.8336.5071.4473.4013.2230.361.20--0.000.0059.9029.63-56.5332.4141.55--
Cooper Companies Inc3.22bn430.60m15.91bn12.00k37.292.2420.794.948.648.6464.62143.670.30431.845.97268,291.704.0714.094.6015.9965.3865.0313.3734.480.709563.360.28920.338620.228.241,135.1960.807.030.00
ABIOMED Inc1.07bn266.76m17.01bn2.00k64.8311.0757.7915.845.825.8223.4134.090.66582.1311.67536,243.6016.5416.9117.9118.7581.3282.1324.8423.457.17--0.000.0021.7418.30-39.4721.24-6.64--
Data as of Dec 03 2022. Currency figures normalised to Smith & Nephew PLC's reporting currency: US Dollar USD

Institutional shareholders

6.62%Per cent of shares held by top holders
HolderShares% Held
Nuance Investments LLCas of 30 Sep 202213.10m3.01%
Fiduciary Management, Inc.as of 30 Sep 20226.99m1.61%
Scharf Investments LLCas of 30 Sep 20222.07m0.48%
Arrowstreet Capital LPas of 30 Sep 20221.74m0.40%
Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Sep 20221.06m0.24%
Magnetar Financial LLCas of 30 Sep 2022820.46k0.19%
Fidelity Management & Research Co. LLCas of 30 Sep 2022777.44k0.18%
Parametric Portfolio Associates LLCas of 30 Sep 2022766.06k0.18%
Strategic Advisers LLCas of 30 Sep 2022763.35k0.18%
Goldman Sachs Asset Management LPas of 30 Sep 2022748.82k0.17%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.